Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Orange, California and other locations
Dates
study started
completion around
Principal Investigator
by Misako Nagasaka, MD

Description

Summary

A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naïve or have progressed after receiving prior therapy for advanced/metastatic disease.

Official Title

Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Keywords

Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, MCLA-129, EGFR inhibitor, NSCLC, C-MET, GC/GEJ, Head and Neck Cancer, Carcinoma, Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Osimertinib, Chemotherapy

Eligibility

Locations

  • University of California, Irvine accepting new patients
    Orange California 92868 United States
  • START Mountain Region completed
    West Valley City Utah 84119 United States
  • Sarah Cannon Research Institute accepting new patients
    Nashville Tennessee 37203 United States

Lead Scientist at UC Irvine

  • Misako Nagasaka, MD
    Associate Clinical Professor, Medicine, School of Medicine. Authored (or co-authored) 191 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Merus N.V.
ID
NCT04868877
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 576 study participants
Last Updated